Last $25.96 USD
Change Today +1.35 / 5.49%
Volume 114.8K
OMED On Other Exchanges
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

oncomed pharmaceuticals inc (OMED) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/21/14 - $39.50
52 Week Low
08/14/14 - $16.57
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

oncomed pharmaceuticals inc (OMED) Related Bloomberg News

View More Bloomberg News

oncomed pharmaceuticals inc (OMED) Related Businessweek News

No Related Businessweek News Found

oncomed pharmaceuticals inc (OMED) Details

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem Cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates under development include Anti-DLL4 (demcizumab, OMP-21M18), a humanized monoclonal antibody that is in three Phase Ib clinical studies for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-VEGF Bispecific, which has completed preclinical trial that targets and inhibits both DLL4 and vascular endothelial growth factor (VEGF); Anti-Notch2/3 (OMP-59R5), a human monoclonal antibody that completed single-agent Phase I trial for the treatment of solid tumor; Anti-Notch1 (OMP-52M51), which is in Phase Ia clinical trials for the treatment of hematologic or solid tumor malignancies; and Anti-Fzd7 (OMP-18R5) that is in Phase I single-agent trial for the treatment of solid tumor patients. Its products also include Fzd8-Fc (OMP-54F28), a proprietary fusion protein based on a truncated form of the Frizzled8 receptor or Fzd8, which is in Phase I single agent trial; and RSPO-LGR, a CSC pathway. OncoMed Pharmaceuticals, Inc. has a research and development agreement with GlaxoSmithKline LLC to develop therapeutic antibody product candidates targeting the Notch signaling pathway, such as anti-Notch2/3 (OMP-59R5) and anti-Notch1 (OMP-52M51). It also has strategic alliances with Bayer Pharma AG to discover, develop, and commercialize anti-CSC biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation to develop and commercialize anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.

91 Employees
Last Reported Date: 03/18/14
Founded in 2004

oncomed pharmaceuticals inc (OMED) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $628.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $487.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $452.4K
Vice President and General Counsel
Total Annual Compensation: $383.8K
Compensation as of Fiscal Year 2013.

oncomed pharmaceuticals inc (OMED) Key Developments

OncoMed Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial of Demcizumab for the Treatment of Non-Small Cell Lung Cancer

OncoMed Pharmaceuticals, Inc. announced that patient dosing has begun in the double-blinded, placebo-controlled, randomized Phase 2 clinical trial of demcizumab (anti-DLL4, OMP-21M18) for the treatment of patients with first-line advanced-stage non-small cell lung cancer (NSCLC). The Phase 2 "DENALI" trial is expected to enroll approximately 200 patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors do not have an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation. Patients will be randomized into one of three study arms to compare the efficacy and safety of demcizumab combined with carboplatin and pemetrexed versus carboplatin and pemetrexed alone. In all three arms, patients will receive carboplatin and pemetrexed for four cycles, followed by pemetrexed maintenance. In addition, patients in Arm 1 will receive the chemotherapy plus placebo, patients in Arm 2 will receive chemotherapy with one truncated course of demcizumab every three weeks for four doses and patients in Arm 3 will receive chemotherapy with two truncated courses of demcizumab with the second truncated course starting at Day 168. The primary endpoint is progression-free survival. Secondary endpoints include response rate, duration of response, overall survival, safety, immunogenicity and pharmacokinetics. The DENALI study will also explore pharmacodynamics and several potential predictive biomarkers. DENALI will be conducted at approximately 60 sites in Europe, the United States and Australia. In OncoMed's Phase 1b clinical study of demcizumab in NSCLC, the combination of demcizumab with pemetrexed and carboplatin was generally well tolerated. No moderate to severe cardiopulmonary adverse events occurred with truncated demcizumab administration. Of 33 patients evaluable for efficacy, one (3%) had a complete response, 15 (45%) had a partial response and 13 (39%) had stable disease per RECIST criteria for an overall clinical benefit rate of 88 percent. Among the 14 evaluable patients who received demcizumab on a truncated dosing schedule, one had a complete response, seven had a partial response, five achieved stable disease and one had progressive disease resulting in an overall clinical benefit rate in this subset of patients of 93%. Eight patients treated with demcizumab at or above the Phase 2 dose schedule had progression-free survival for greater than 300 days. Final clinical data from this Phase 1b trial are anticipated to be presented at a medical meeting in 2015.

FDA Grants Orphan Drug Designations to OncoMed's Tarextumab for the Treatment of Pancreatic and Small Cell Lung Cancer

OncoMed Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration'sOffice of Orphan Products Development (OOPD) has granted orphan drug designation to tarextumab (anti-Notch 2/3, OMP-59R5) for the treatment of both pancreatic cancer and small cell lung cancer. OncoMed is currently enrolling patients in a randomized Phase 2 clinical trial of tarextumab with gemcitabine plus Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin bound) in patients with first-line advanced pancreatic cancer. In January 2015, OncoMed announced positive final Phase 1b clinical and biomarker data from its study of tarextumab in combination with standard of care in pancreatic cancer. Tarextumab was well tolerated with manageable side effects and the three drug combination achieved an overall clinical benefit rate (defined as partial responses and stable disease) of 73% (21 of 29 patients). Biomarker analyses showed that among patients whose tumor samples had elevated levels of Notch3 gene expression suggestions of higher response rates and longer survival were noted. For patients with high Notch3 expression, median progression-free and overall survival were 6.6 months and 14.6 months, respectively.

OncoMed Pharmaceuticals, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 08:05 AM

OncoMed Pharmaceuticals, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 08:05 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Paul J. Hastings, Chairman, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMED:US $25.96 USD +1.35

OMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMED.
View Industry Companies

Industry Analysis


Industry Average

Valuation OMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.6x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOMED PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at